Amarin reveals multiple abstracts at the European Society of Cardiology Congress 2026 in Munich, highlighting analyses from REDUCE-IT and broader research on icosapent ethyl (EPA) and cardiovascular risk factors.

A post hoc REDUCE-IT analysis presented at ESC 2026 shows that highly adherent patients who stayed on EPA for at least 1.5 years achieved roughly a 30% relative risk reduction in the primary composite cardiovascular endpoint.

The press release frames ongoing exploration of EPA’s cardiovascular impact through adherence, biomarkers, and potential mechanisms, building on REDUCE-IT findings.

Among secondary prevention participants who stopped EPA after about 2.3 years, a persistent 'legacy' effect remained, with no reduction in hazard ratio difference over the following 1 to 4 years off treatment.

In the legacy-effect analysis, 1,318 participants with at least three months on EPA who stopped after a mean of 2.3 years still showed a hazard ratio of 0.73 after stopping, with effects persisting on average 2.1 years off-treatment.

The high-adherence group (around 6,921 participants) displayed a 29–30% relative risk reduction, implying that better adherence may enhance benefit.

Experts caution that these results are exploratory but suggest durable cardiovascular protection even after stopping therapy, supporting long-term adherence and potential legacy benefits for high-risk patients.

The studies emphasize residual cardiovascular risk and support using EPA as a complementary therapy in appropriate patients, aligning with global professional society positions on EPA’s role in risk reduction.

Key collaborators include Deepak L. Bhatt and other international researchers, with specific presentation times and locations noted for August 28–30.

Forward-looking statements flag risks and uncertainties, noting ongoing efforts to expand access and reimbursement for VASCEPA/VAZKEPA.

In the overall REDUCE-IT cohort of 8,179 participants, intention-to-treat analysis showed a 25% relative risk reduction in the primary endpoint with EPA versus placebo.

The release provides REDUCE-IT background, trial design, and major publications, along with product information, indications, safety considerations, and global approvals for VASCEPA/VAZKEPA.